Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on May 10, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi077
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/5/251    most recent
hyi077v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chang, H. M.
Right arrow Articles by Kang, Y.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, H. M.
Right arrow Articles by Kang, Y.-K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received March 31, 2005
Accepted April 1, 2005

Original Article

Phase II Study of Paclitaxel and Carboplatin in Advanced Gastric Cancer Previously Treated with 5-Fluorouracil and Platinum

Heung Moon Chang 1*, Tae Won Kim 1, Baek-Yeol Ryu 2, Seong-Jun Choi 2, Yeon Hee Park 2, Jung Shin Lee 1, Woo Kun Kim 1, and Yoon-Koo Kang 1

1 Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

* To whom correspondence should be addressed.
Heung Moon Chang, E-mail: changhm{at}amc.seoul.kr


  Abstract

Background: The combination of paclitaxel and carboplatin has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-fluorouracil and platinum.

Methods: Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel (200 mg/m2 for 3 h) and carboplatin [area under the concentration-time curve (AUC = 6)] on day 1 and in 21 day cycles.

Results: A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths.

Conclusions: Combination chemotherapy with paclitaxel and carboplatin is feasible in patients with advanced gastric cancer who were previously treated with 5-fluorouracil and platinum.

Keywords: gastric cancer; carboplatin; paclitaxel.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
Y. H. Kim, K. Yamaguchi, Y.-J. Bang, H. Takiuchi, W. K. Kang, A. Sato, Y.-K. Kang, J. Sakamoto, C. Abe, and Y. Sakata
Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym054v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.